Form 8-K - Current report:
SEC Accession No. 0001104659-24-125774
Filing Date
2024-12-05
Accepted
2024-12-05 08:10:32
Documents
15
Period of Report
2024-12-05
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2430229d1_8k.htm   iXBRL 8-K 30320
2 EXHIBIT 99.1 tm2430229d1_ex99-1.htm EX-99.1 14888
6 GRAPHIC tm2430229d1_ex99-1img001.jpg GRAPHIC 3983
  Complete submission text file 0001104659-24-125774.txt   232192

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syn-20241205.xsd EX-101.SCH 3042
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20241205_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20241205_pre.xml EX-101.PRE 22378
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2430229d1_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 241527892
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)